Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario--(BUSINESS WIRE)-- Triumvira Immunologics, Inc. (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022, in Boston and virtually. The presentations will include updated clinical data from its Phase 1/2 trial of TAC01-HER2 in patients with solid tumors and preclinical data on T cell therapy candidates TAC01-CLDN18.2 and GUCY2C-TAC T.

Details of presentations:

Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors
Abstract #: 760

Title: Development of GUCY2C-TAC T cells for the treatment of colorectal cancer
Abstract #: 201

Title: Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors
Abstract #: 261

Title: Preclinical studies of TAC01-CLDN18.2, an autologous Claudin 18.2-directed TAC T cell therapy, in the treatment of gastric cancer
Abstract #: 294

Titles for abstracts are available on the SITC Annual Meeting website. Full abstract content will be available online in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Nov. 7, 2022 at 8:00 a.m. EST.

Posters will be available in the poster hall and virtually to registered attendees of the SITC Annual Meeting starting Nov. 10, 2022 at 9:00 a.m. EST, and will be available online for eight weeks after the meeting ends on Nov. 12, 2022. In the poster hall onsite, odd numbered posters will be displayed on Thursday, Nov. 10, and even numbered posters will be displayed on Friday, Nov. 11.

A copy of the presentations will also be available after the closure of the meeting on Nov. 12, 2022 at 1:05 p.m. EST, under the Presentations & Publications tab of the News & Resources section of the Company’s website.

About Triumvira Immunologics

Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira’s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon® Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.


Investor Relations:
Stephanie Carrington
ICR Westwicke

Media Relations:
Karen Chase
ICR Westwicke


Source: Triumvira Immunologics

Back to news